Blue Earth Therapeutics, a clinical-stage radiopharmaceutical company and University College London (UCL) today announced ...
Enables cutting-edge collaborative clinical and translational research to accelerate new radiopharmaceutical drugs to market Provides an integrated, one-stop expert resource to support all stages of ...
Researchers at the University of Pittsburgh, UPMC Hillman Cancer Center and the National Cancer Institute report that ...
1d
Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using ...
NorthStar will provide PDRadiopharma, a wholly-owned subsidiary of PeptiDream, with a broad range of research and development services to support PeptiDream’s internal peptide-RI conjugate programs.
Researchers at Weill Cornell Medicine have led a phase 1 trial of a new drug that delivers potent radiation therapy directly and specifically to cancer cells in patients with advanced prostate cancer.
Korea Joongang Daily on MSN
Experimental 'radiation missile' therapy offers hope to children with hard-to-treat cancers
Funded by donations from the family of the late Samsung Chairman Lee Kun-hee, the treatment injects patients with a drug that ...
Radiopharmaceuticals are rapidly becoming one of the most dynamic areas of oncology drug development. By combining molecular targeting with controlled radiation delivery, these therapies introduce a ...
A new database of S-values for radiopharmaceutical therapy could prove particularly useful when treating metastatic bone cancer, in which cells in the primary tumour (A) invade surrounding tissues (B) ...
If you would like to learn more about the IAEA’s work, sign up for our weekly updates containing our most important news, multimedia and more. While identifying TB in the lung – its most common form – ...
A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a ...
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results